Rena Ni Made Renny A, Wibawa I Dewa Nyoman
Department of Internal Medicine, Faculty of Medicine, University of Udayana-Sanglah Hospital, Jl. PB. Sudirman, Denpasar Bali, Indonesia.
Acta Med Indones. 2010 Jul;42(3):162-8.
Albumin infusions have been used for many years in the management of patients with decompensated cirrhosis in an attempt to reduce the formation of ascites, to improve circulatory and renal function, or in SBP patients. While some of these indications for albumin infusions are supported by the results of randomised studies, others are based on clinical experience and have not been proved in prospective investigations. Therefore, the use of albumin infusions in patients with cirrhosis is still controversial. However, despite the controversies, the use of albumin at least has been proven to be safe. Some guidelines recommended the use of albumin infusion in decompensated cirrhosis with spontaneous bacterial peritonitis, hepatorenal syndrome, large volume parecentesis and decompensated cirrhosis with complications.
多年来,白蛋白输注一直用于失代偿期肝硬化患者的治疗,旨在减少腹水形成、改善循环和肾功能,或用于自发性细菌性腹膜炎(SBP)患者。虽然白蛋白输注的其中一些适应证得到了随机研究结果的支持,但其他适应证是基于临床经验,尚未在前瞻性研究中得到证实。因此,肝硬化患者使用白蛋白输注仍存在争议。然而,尽管存在争议,但白蛋白的使用至少已被证明是安全的。一些指南建议在失代偿期肝硬化合并自发性细菌性腹膜炎、肝肾综合征、大量腹腔穿刺放液以及失代偿期肝硬化合并并发症时使用白蛋白输注。